344 Phase 3 trial of pembrolizumab and enzalutamide versus enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) (KEYNOTE-641)

• Arnulf Stenzl,
• Julie Nicole Graff,
• Joseph Burgents,
• Li Wen Liang

Affiliations

Arnulf Stenzl

Aff7 Dept. of UrologyUniversity Hospital, University of Tuebingen Germany

Julie Nicole Graff

1Knight Cancer Institute, Oregon Health, Portland, OR, USA

Joseph Burgents

2Merck and Co., Inc., Kenilworth, NJ, USA

Li Wen Liang

3MSD China, Beijing, China